Revvity, Inc traded at $95.57 this Thursday February 12th, decreasing $5.53 or 5.47 percent since the previous trading session. Looking back, over the last four weeks, Revvity lost 13.23 percent. Over the last 12 months, its price fell by 15.33 percent. Looking ahead, we forecast Revvity, Inc to be priced at 98.47 by the end of this quarter and at 89.68 in one year, according to Trading Economics global macro models projections and analysts expectations.
PerkinElmer, Inc. is a provider of products, services and solutions for the diagnostics, life sciences and applied markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides products and services targeted towards the life sciences and applied markets. The Diagnostics segment develops diagnostics, tools and applications focused on clinically oriented customers, especially within the reproductive health, immunodiagnostics and applied genomics markets. The Company provides early detection for genetic disorders from pregnancy to early childhood, and infectious disease testing for the diagnostics market. It offers its products under various brand names, including AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific, BoBs, chemagic, Chitas, Datalytix, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROline, EUROPattern, FragilEase, Genoglyphix, GSP, and Haoyuan.